AVITA Medical Announces First Clinical Publication Demonstrating Accelerated Autograft Readiness with Cohealyx™

Rhea-AI Summary

AVITA Medical announced the first clinical publication of Cohealyx, their collagen-based dermal matrix, in the Journal of Surgery. The study demonstrated significantly faster wound bed vascularization and autograft readiness compared to conventional methods, achieving results in 5-10 days versus the typical 2-4 weeks. In a case series at Ohio State University Wexner Medical Center, two patients with complex hand wounds showed excellent outcomes, with one patient achieving vascularization by day 5 and autografting by day 7, while the second patient reached vascularization by day 10 and autografting by day 13. Cohealyx, developed using proprietary TetraPure Technology, contains crosslinked collagen types I and III, supporting optimal cellular migration and rapid revascularization. The accelerated timeline could improve clinical outcomes by enabling earlier wound closure and reducing patient complications.

Positive

• Significantly faster wound bed vascularization achieved in 5-10 days vs conventional 2-4 weeks
• Successful clinical validation of preclinical findings showing accelerated healing
• Excellent patient outcomes in both test cases with full recovery
• Potential for reduced patient complications and improved clinical efficiency

Negative

• Limited sample size of only two patients in the clinical study
• Study results are preliminary and may require larger trials for validation

Insights

Medical Device Analyst

AVITA's Cohealyx shows remarkable 70-80% reduction in autograft preparation time, validating their wound care technology with significant clinical implications.

The first clinical publication for AVITA Medical's Cohealyx dermal matrix demonstrates a substantial advancement in wound management. The data from Ohio State University shows Cohealyx achieved wound bed vascularization in just 5-10 days versus the conventional 14-28 days - representing a 70-80% reduction in preparation time before autografting can occur.

This accelerated timeline addresses a critical bottleneck in wound care. The faster a wound bed is ready for autografting, the sooner definitive closure can be achieved, which reduces infection risk, decreases hospital stays, and improves functional outcomes. The hand wounds treated in this study are particularly challenging cases where functional recovery is paramount.

AVITA's proprietary TetraPure Technology, using crosslinked collagen types I and III, appears to be the differentiating factor enabling superior cellular migration and revascularization. While this publication only details two patients, the dramatic reduction in time-to-autograft readiness validates previous preclinical findings and establishes proof-of-concept in humans.

From a market perspective, this positions Cohealyx as potentially disruptive in the $1.5+ billion dermal substitute market. The technology complements AVITA's existing RECELL autologous cell harvesting platform, creating a more comprehensive wound management solution. The accelerated treatment timeline could translate to significant healthcare cost savings through reduced hospital stays and fewer complications, making this advancement meaningful for patients, providers, and payers alike.

VALENCIA, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced the first clinical publication evaluating Cohealyx™, an AVITA Medical-branded collagen-based dermal matrix, published in the Journal of Surgery (Akpunonu et al., 2025). According to the investigators, Cohealyx demonstrated significantly faster wound bed vascularization and autograft readiness compared to conventional dermal matrices, achieving readiness within 5 to 10 days versus the typical two to four weeks.

In the case series conducted at The Ohio State University Wexner Medical Center, two patients with complex, full-thickness hand wounds were treated with Cohealyx. One patient achieved a well-vascularized wound bed by day 5, enabling autografting by day 7. The second patient reached robust re-vascularization by day 10 and proceeded to autografting on day 13. Both patients had excellent skin graft take outcomes and functional recovery. According to the publication, these outcomes demonstrate accelerated integration and wound bed vascularization, potentially facilitating earlier definitive wound closure, which can significantly reduce patient burden and lower associated complication risks.

“This first clinical publication provides compelling validation of our preclinical findings and positions Cohealyx as a significant advancement in wound management,” said Jim Corbett, Chief Executive Officer of AVITA Medical. “The ability to achieve autograft readiness in days rather than weeks represents a significant breakthrough. This accelerated timeline can meaningfully improve clinical outcomes by enabling earlier definitive closure, reducing patient burden, enhancing clinical efficiency, and ultimately elevating the standard of care for complex wounds.”

Cohealyx is bioengineered using proprietary TetraPure^™ Technology. It features crosslinked, purified collagen types I and III, supporting optimal cellular migration, rapid revascularization, and effective integration within the wound bed. Preclinical studies demonstrated wound bed readiness as early as day 7¹, and this publication represents the first clinical validation of those findings.

The full paper, titled “A Bovine Dermal Collagen Matrix (BDCM) Advances Readiness to Autografting: A Case Series,” is available online at https://www.gavinpublishers.com/article/view/a-bovine-dermal-collagen-matrix-bdcm-advances-readiness-to-autografting-a-case-series. 

References

¹ Bush KA, Nsiah BA, Jay JW. Bovine Dermal Collagen Matrix Promotes Vascularized Tissue Generation Supporting Early Definitive Closure in Full-Thickness Wounds: A Pre-clinical Study. Cureus. 2025;17(3):e81517.

About AVITA Medical, Inc.
AVITA Medical^® is a leading therapeutic acute wound care company delivering transformative solutions. Our technologies are designed to optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of our platform is the RECELL System^®, approved by the FDA for the treatment of thermal burn wounds and full-thickness skin defects. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin^™ Cells, offering an innovative solution for improved clinical outcomes at the point of care. In the U.S., AVITA Medical also holds the exclusive rights to manufacture, market, sell, and distribute PermeaDerm^®, a biosynthetic wound matrix, and the exclusive rights to market, sell, and distribute Cohealyx^™, an AVITA Medical-branded collagen-based dermal matrix.

In international markets, the RECELL System is approved to promote skin healing in a wide range of applications including burns and full-thickness skin defects. The RECELL System, excluding RECELL GO^®, is TGA-registered in Australia, has received CE mark approval in Europe, and has PMDA approval in Japan.

To learn more, visit www.avitamedical.com.

Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Forward-looking statements generally may be identified by the use of words such as “anticipate,” “expect,” “intend,” “could,” “would,” “may,” “will,” “believe,” “continue,” “estimate,” “look forward,” “forecast,” “goal,” “target,” “project,” “outlook,” “guidance,” “future,” and similar words or expressions, and the use of future dates. Forward-looking statements include, but are not limited to, statements relating to the timing and realization of regulatory approvals of our products; physician acceptance, endorsement, and use of our products; failure to achieve the anticipated benefits from approval or adoption of our products; the effect of regulatory actions; product liability claims; risks associated with international operations and expansion; and risks of other business effects, including the effects of industry, as well as other economic or political conditions outside of the Company’s control. These statements are made as of the date of this release, and the Company undertakes no obligation to publicly update or revise any of these statements, except as required by law. For additional information and other important factors that may cause actual results to differ materially from forward-looking statements, please see the “Risk Factors” section of the Company’s latest Annual Report on Form 10-K and other publicly available filings for a discussion of these and other risks and uncertainties.

Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.

Investor & Media Contact:
Jessica Ekeberg
investor@avitamedical.com
media@avitamedical.com

FAQ

What is RCEL's Cohealyx and how does it work?

Cohealyx is AVITA Medical's collagen-based dermal matrix that uses proprietary TetraPure Technology with crosslinked collagen types I and III to support cellular migration and rapid revascularization for wound healing.

How much faster is Cohealyx compared to conventional wound treatments?

Cohealyx achieves wound bed vascularization and autograft readiness in 5-10 days, compared to the conventional timeline of 2-4 weeks.

What were the results of RCEL's Cohealyx clinical study?

In a case series of two patients with complex hand wounds, one achieved vascularization by day 5 and autografting by day 7, while the second reached vascularization by day 10 and autografting by day 13, both with excellent recovery outcomes.

What are the potential benefits of AVITA Medical's Cohealyx for patients?

Cohealyx can potentially improve clinical outcomes through earlier definitive wound closure, reduced patient burden, enhanced clinical efficiency, and lower associated complication risks.

Where was the Cohealyx clinical study conducted?

The clinical case series was conducted at The Ohio State University Wexner Medical Center and published in the Journal of Surgery.